Skip to main content
Log in

Frequency and Clinical Relevance of Drug Interactions with Lovastatin and Simvastatin

An Observational Database Study

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Concomitantly used cytochrome P450 (CYP) 3A4 inhibitors and inducers have been shown to alter the plasma concentrations of the HMG-CoA reductase inhibitors (‘statins’) lovastatin and simvastatin. Myopathy is a serious adverse effect of statins. Concurrent use of statins with fibrates in particular seems to increase the risk of this adverse effect.

Objective: To evaluate the incidence and clinical consequences of the use of lovastatin or simvastatin with concomitant CYP3A4 inhibitors and inducers, and with fibrates.

Methods: An observational database study of hospitalized patients treated in Turku University Hospital, Turku, Finland, covering the period 1 July 1996 to 30 June 2003, and of nationwide community data from the Finnish Prescription Register over the period 1 April to 30 June 2001 was conducted. In the hospital setting, the study population comprised 71 025 patients (93 467 treatment periods) over 7 years, with a total of 5320 treatment periods of lovastatin or simvastatin. The community-based, nationwide survey included all reimbursed prescriptions of lovastatin and simvastatin (n = 91 656) in Finland during a 3-month period. The frequency of drug-drug interactions involving lovastatin or simvastatin was studied. The efficacy and safety of the various statin/concomitant drug combinations was estimated by evaluating patients’ laboratory data.

Results: Concomitant use of lovastatin or simvastatin with interacting medication was detected in 13.3% (704) and 6.9% (6338) of patients in hospital and community settings, respectively. Co-administration of lovastatin or simvastatin with CYP3A4 inhibitors or inducers did not have a clinically significant effect on serum lipid values. Plasma creatine kinase (CK) activity was significantly higher in patients receiving a statin and a fibrate compared with a statin only (433 U/L vs 209 U/L, p = 0.053). Co-administration of a statin and a CYP3A4 inhibitor did not increase CK activity.

Conclusion: Although the pharmacokinetic interactions between lovastatin or simvastatin and CYP3A4 inhibitors and inducers are substantial, their clinical relevance seems to be limited, at least with lower statin doses. However, combining statins with fibrates, especially gemfibrozil, clearly increases the potential for muscular toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278: 313–21

    Article  PubMed  CAS  Google Scholar 

  2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22

    Article  PubMed  CAS  Google Scholar 

  3. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50–7

    Article  PubMed  Google Scholar 

  4. Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001; 323: 359

    Article  Google Scholar 

  5. SoRelle R. Baycol withdrawn from market. Circulation 2001; 104: E9015–6

    Article  Google Scholar 

  6. Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72: 685–91

    Article  PubMed  CAS  Google Scholar 

  7. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–41

    Article  PubMed  CAS  Google Scholar 

  8. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53

    Article  PubMed  CAS  Google Scholar 

  9. Wang RW, Kari PH, Lu AY, et al. Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355–61

    Article  PubMed  CAS  Google Scholar 

  10. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191–9

    PubMed  CAS  Google Scholar 

  11. Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592–7

    Article  PubMed  CAS  Google Scholar 

  12. Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004; 59: 879–82

    Article  PubMed  CAS  Google Scholar 

  13. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadmin-istered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140–6

    Article  PubMed  CAS  Google Scholar 

  14. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997; 31: 859–63

    PubMed  CAS  Google Scholar 

  15. Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410–3

    Article  PubMed  CAS  Google Scholar 

  16. Campana C, Iacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29: 235–9

    PubMed  CAS  Google Scholar 

  17. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–21

    Article  PubMed  CAS  Google Scholar 

  18. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369–77

    Article  PubMed  CAS  Google Scholar 

  19. Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267–74

    Article  PubMed  CAS  Google Scholar 

  20. Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92

    Article  PubMed  CAS  Google Scholar 

  21. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177–82

    Article  PubMed  CAS  Google Scholar 

  22. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998; 91: 202–5

    Article  PubMed  CAS  Google Scholar 

  23. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61

    Article  PubMed  CAS  Google Scholar 

  24. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22: 295–7

    PubMed  CAS  Google Scholar 

  25. Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J 2003; 96: 1034–5

    Article  PubMed  Google Scholar 

  26. Thompson M, Samuels S. Rhabdomyolysis with simvastatin and nefazodone. Am J Psychiatry 2002; 159: 1607

    Article  PubMed  Google Scholar 

  27. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997; 277: 296–7

    Article  PubMed  CAS  Google Scholar 

  28. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3: 35–40

    Article  PubMed  CAS  Google Scholar 

  29. Spina E, Martines C, Fazio A, et al. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther Drag Monit 1991; 13: 109–12

    Article  CAS  Google Scholar 

  30. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253–7

    Article  PubMed  CAS  Google Scholar 

  31. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drag interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82

    Article  PubMed  CAS  Google Scholar 

  32. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–70

    Article  PubMed  CAS  Google Scholar 

  33. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122–9

    Article  PubMed  CAS  Google Scholar 

  34. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5

    Article  PubMed  CAS  Google Scholar 

  35. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403–4

    Article  PubMed  Google Scholar 

  36. WHO Collaborating Centre for Drag Statistics Methodology [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2007 Nov 16]

  37. Graer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811–5

    Article  Google Scholar 

  38. Arnadottir M, Eriksson LO, Germershausen JI, et al. Low-dose simvastatin is a well-tolerated and efficacious cholesterollowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68: 57–62

    Article  PubMed  CAS  Google Scholar 

  39. Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995; 14: 613–22

    PubMed  CAS  Google Scholar 

  40. Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10: MT50–2

    PubMed  CAS  Google Scholar 

  41. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999; 75: 359–60

    PubMed  CAS  Google Scholar 

  42. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340–5

    Article  PubMed  CAS  Google Scholar 

  43. Illingworth DR, O’Malley JP. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990; 39: 403–9

    Article  PubMed  CAS  Google Scholar 

  44. Tokola R, Palva E, Sommarberg L. Statins and muscular adverse drag reactions [online]. Available from URL: http://www.nam.fi/uploads/english/Publications/Tabu/tabu52002_eng.pdf [Accessed 2007 Dec 6]

Download references

Acknowledgements

The work reported here was supported by Turku University Hospital Grant EVO13390, The Finnish Cultural Foundation, The Regional Fund on Varsinais-Suomi and Research Foundation of Orion Corporation. Dr Laine has received speaker fees from Merck, Astra Zeneca and Pfizer, and has stock or stock options in Medifront Ltd, Finland. The other authors have declared no potential conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tuire Tirkkonen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tirkkonen, T., Ryynänen, A., Vahlberg, T. et al. Frequency and Clinical Relevance of Drug Interactions with Lovastatin and Simvastatin. Drug-Safety 31, 231–240 (2008). https://doi.org/10.2165/00002018-200831030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831030-00004

Keywords

Navigation